Hot Features
Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
SR Pharma plc Research Update London 23 December 2003 - Corixa Corporation (Corixa) and Genesis Research and Development Corporation Limited (Genesis) announced yesterday that they had...
SR Pharma plc Holding in Company London 16 December 2003 - SR Pharma plc ("the Company") was informed today by the Royal Bank of Scotland Group plc that the Royal Bank of Scotland Group plc and...
SR Pharma plc and EiRx Therapeutics Ltd sign research deal `New molecules for potential cancer treatments' London, 1 December 2003 - SR Pharma and EiRx Therapeutics today announced that they...
SR PHARMA PLC UNAUDITED INTERIM RESULTS FOR THE 6 MONTHS ENDED 30 JUNE 2003 SR Pharma plc, the London based biopharmaceutical company, today announces its unaudited interim results for the six...
SR Pharma and Genesis Research Initiate Phase II Trial of AVAC(tm) in Childhood Eczema London and Auckland, 10 September 2003 - London-based biopharmaceutical company SR Pharma (LSE: SPA) and its...
Death of non-executive director of SR Pharma plc London, 23 July 2003 - SR Pharma plc regretfully announces the death of Professor Tim Chard who was a non-executive director of the company...
RNS Number:7085N SR Pharma PLC 18 July 2003 18th July, 2003 TO: CITY EDITORS FOR IMMEDIATE RELEASE SR Pharma plc Resignation of executive director SR Pharma plc today announces...
SR Pharma completes enrolment of phase II clinical trial for asthma London, UK. 24 June 2003*SR Pharma plc (LSE: SPA) today announces the completion of enrolment in its phase II European clinical...
SR Pharma Appoints Dr David Hill As Chief Executive Officer London, UK. 19 May 2003SR Pharma plc (LSE: SPA) announces the appointment today of Dr David Hill as Chief Executive Officer and a member...
SR Pharma Annual General Meeting London, UK. 19 May 2003 At today's Annual General Meeting, Chairman Eric Boyle said: "SR Pharma retains a robust cash position and a well diversified product...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Premium
